Sage Therapeutics, Inc. (SAGE) Initiated at Goldman and JP Morgan

Shares of Sage Therapeutics, Inc. (SAGE) are up almost 5% in premarket Monday trading after analysts at JP Morgan (JPM) initiated the company with a ‘Overweight’ rating. The 12-month target price has been set at $42.00. SAGE was also initiated with a ‘Neutral’ at Goldman Sachs (GS) and a ‘Buy’ at Canaccord Genuity with both […] View the full post at: Sage Therapeutics, Inc. (SAGE) Initiated at Goldman and JP Morgan Related posts: Goldman Sachs to Pay $60 mln in Subprime Settlement Dick Bove: Goldman Sachs Execs Will Be Ousted Because of Their “Ineptitude” Goldman CDO case could be tip of iceberg